rss
J Clin Pathol 2008;61:272-277 doi:10.1136/jcp.2007.049684
  • Original article

Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions

  1. S Schwarz1,
  2. M Rechenmacher1,
  3. T Filbeck2,
  4. R Knuechel3,
  5. H Blaszyk4,
  6. A Hartmann1,
  7. G Brockhoff1
  1. 1
    Department of Pathology, University of Regensburg, Regensburg, Germany
  2. 2
    Department of Urology, Hospital Eichstaett, Eichstaett, Germany
  3. 3
    Department of Pathology, University of Aachen, Aachen, Germany
  4. 4
    Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont, USA
  1. Gero Brockhoff, PhD, Department of Pathology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; gero.brockhoff{at}klinik.uni-regensburg.de
  • Accepted 23 July 2007
  • Published Online First 10 August 2007

Abstract

Aims: During the past 10 years, multitarget fluorescence in situ hybridisation has been established as a valuable adjunct in the cytological diagnosis of precancerous and malignant lesions of the urinary tract. The aim of the present study was to define its value in detecting chromosomal imbalances in patients with various flat urothelial lesions in routine paraffin-embedded bladder biopsy samples. In addition, the HER2 gene amplification and HER2 expression pattern were examined, since alterations of the HER2 expression patterns have been demonstrated in invasive bladder cancer.

Methods: 29 samples of normal urothelium and 86 flat urothelial lesions (hyperplasia, reactive atypia, dysplasia and carcinoma in situ (CIS)) from 73 patients were analysed patients using tissue microarrays and centromeric probes for chromosomes 3, 7 and 17, and gene-specific probes for 9p21/P16 and HER2 (UroVysion, PathVysion). The expression of HER2 was studied by immunohistochemistry.

Results: Polysomy of at least one of the chromosomes was found in about half of the dysplastic cells, and in more than 90% of cells in CIS or cells in invasive bladder tumours. Polysomic cells were found in only 17% of urothelial hyperplasia, reactive atypia and normal urothelium of healthy patients, whereas about 30% of non-neoplastic lesions in patients with concomitant urothelial carcinoma showed polysomy of at least one chromosome. These alterations indicate a field effect and are associated with synchronous development of dysplastic lesions of a higher grade. Deletion of the P16 locus was most frequently observed in aneuploid lesions, whereas overexpression of HER2 was found in 10–20% of invasive urothelial carcinomas, and only occasionally in CIS (5%). An altered HER2 expression pattern was present in non-neoplastic lesions (25%).

Conclusions: UroVysion fluorescence in situ hybridisation is a valuable tool for the detection of genetically unstable flat urothelial lesions, and can help to resolve difficult cases, particularly the differential diagnosis of reactive atypia and dysplasia.

Footnotes

  • Funding: Supported by: Deutsche Forschungsgemeinschaft, Project Knue263-9/1; Dr.-Pfleger-Stiftung, Bamberg, Project 1058-2.

  • Competing interests: None.

Responses to this article

  • Author’ Reply
    • Gero Brockhoff
    J Clin Pathol published online October 2, 2008
  • Immunohistochemistry of HER2
    • IRENA SREBOTNIK KIRBIŠ
    J Clin Pathol published online October 2, 2008

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. jcp.2007.049684v1
    2. 61/3/272 most recent

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.